These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7542033)

  • 1. Prostate cancer screening (United States).
    Waterbor JW; Bueschen AJ
    Cancer Causes Control; 1995 May; 6(3):267-74. PubMed ID: 7542033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program.
    Smart CR
    Cancer; 1997 Nov; 80(9):1835-44. PubMed ID: 9351557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths.
    Neppl-Huber C; Zappa M; Coebergh JW; Rapiti E; Rachtan J; Holleczek B; Rosso S; Aareleid T; Brenner H; Gondos A;
    Ann Oncol; 2012 May; 23(5):1325-1334. PubMed ID: 21965474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of increasing detection in the rising incidence of prostate cancer.
    Potosky AL; Miller BA; Albertsen PC; Kramer BS
    JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpreting recent trends in prostate cancer incidence and mortality.
    Gann PH
    Epidemiology; 1997 Mar; 8(2):117-20. PubMed ID: 9229198
    [No Abstract]   [Full Text] [Related]  

  • 6. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
    Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
    J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of screening on incidence and mortality of prostate cancer in the United States.
    Potosky AL; Feuer EJ; Levin DL
    Epidemiol Rev; 2001; 23(1):181-6. PubMed ID: 11588846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen: the new early detection test for prostate cancer.
    Greco KE; Blank B
    Nurse Pract; 1993 May; 18(5):30-8. PubMed ID: 7689192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.
    Brawley OW
    Cancer; 1997 Nov; 80(9):1857-63. PubMed ID: 9351560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 12. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
    Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
    Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
    Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
    Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinoma of the prostate: overview of the most common malignancy in men.
    Carson CC
    N C Med J; 2006; 67(2):122-7. PubMed ID: 16752715
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate cancer in Czech Republic 1959-1992. Descriptive survey.
    Celko AM
    Cent Eur J Public Health; 1995 Aug; 3(3):119-23. PubMed ID: 8535365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening. Why the controversy?
    Walther PJ
    Surg Oncol Clin N Am; 1995 Apr; 4(2):315-34. PubMed ID: 7540938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
    Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
    Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
    Reissigl A; Horninger W; Fink K; Klocker H; Bartsch G
    Cancer; 1997 Nov; 80(9):1818-29. PubMed ID: 9351555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.